Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions (Details Textual)

v3.20.4
Note 4 - Acquisitions (Details Textual) - Changzhou Eminence Biotechnology [Member] - USD ($)
$ in Thousands
Oct. 20, 2020
Oct. 02, 2020
Dec. 31, 2020
Business Acquisition, Percentage of Voting Interests Acquired 47.60%    
Business Combination, Consideration Transferred, Total $ 9,800    
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value 9,000   $ 8,985
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount 9,800    
Developed Technology Rights [Member]      
Finite-Lived Intangible Asset, Useful Life (Year)   13 years  
Customer Relationships [Member]      
Finite-Lived Intangible Asset, Useful Life (Year)   10 years  
Minimum [Member]      
Variable Interest Entity, Financial or Other Support Expected Amount 8,000    
Maximum [Member]      
Variable Interest Entity, Financial or Other Support Expected Amount $ 13,000